ERNA — Ernexa Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 748592 ·
Last close
$5.03
Market Cap
$5.87M
52W High
$11.96
52W Low
$3.28
ADV30
939,130
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | 0 | -3,546,000 | -5,506,000 | 10,543,000 | 9,177,000 | 3,684,000 |
| Dec 2025 | 0 | 0 | -2,094,000 | -1,502,000 | 5,834,000 | 1,884,000 | 3,433,000 |
| Sep 2025 | 0 | 0 | -1,993,000 | -1,240,000 | 6,172,000 | 3,047,000 | 2,602,000 |
| Jun 2025 | 0 | 0 | -2,501,000 | -3,139,000 | 7,584,000 | 4,315,000 | 3,140,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-7,216,000
Investing CF
$-39,000
Financing CF
$14,514,000
CapEx
$-17,000
Dividends Paid
$8,000
Buybacks
—
EPS Diluted TTM
$-83.71
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-251,142,000
Inventory
—
Receivables
$95,000
ST Investments
—
EBIT TTM
$-14,917,000
Pretax Income TTM
$-11,480,000
Interest Exp TTM
$3,483,000
Analysts
1
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -9,319,000 | -14,084,000 | 5,834,000 | 3,433,000 | — | -7,017,000 |
| Dec 2024 | 582,000 | -17,250,000 | -44,539,000 | 5,269,000 | 3,568,000 | — | -15,836,000 |
| Dec 2023 | 68,000 | -20,675,000 | -21,668,000 | 49,132,000 | 46,899,000 | — | -20,408,000 |
| Dec 2022 | 0 | -26,947,000 | -24,579,000 | 22,279,000 | 10,172,000 | — | -20,976,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-9.60
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ACXP | Acurx Pharmaceuticals, Inc. | $6.02M | $1.40 | — |
| GELS | Gelteq Ltd | $5.70M | $0.53 | — |
| PCSA | Processa Pharmaceuticals, Inc. | $6.06M | $2.17 | — |
| PULM | Pulmatrix, Inc. | $5.66M | $1.55 | — |
| NCNA | NuCana plc | $6.12M | $1.47 | — |
News headlines (Yahoo Finance, 1h cache)
Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies
2026-07-24 13:20 · Yahoo
Ernexa Therapeutics shares soar 30% after independent study validates cancer therapy (ERNA)
2026-07-15 13:43 · Yahoo
Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients
2026-06-25 13:15 · Yahoo
Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study
2026-06-17 12:47 · Yahoo
Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development
2026-05-27 12:11 · Yahoo
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity
2026-05-20 12:31 · Yahoo
Ernexa Therapeutics (ERNA) Preclinical Data Shows 100% Survival and Complete Tumor Clearance in Ovarian Cancer Models
2026-05-06 14:40 · Yahoo
Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models
2026-05-06 12:33 · Yahoo
Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split
2026-04-30 13:00 · Yahoo
Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026
2026-03-31 12:55 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.